Panacea Biotech

US International Development Finance Corporation (DFC) has committed a long-term loan of up to USD 20 million to Panacea Biotec, the company said on Thursday. Panacea is expanding the manufacturing capacity for drug substance antigens used in its hexavalent vaccine EasySix to meet future demand from UN agencies and public health organisations. DFC has agreed to provide a long-term loan of up to USD 20 million to the company to help finance this project, the biotechnology firm said in a regulatory filing. DFC's financing will enable Panacea Biotec to expedite the completion of the ongoing expansion and supply the hexavalent vaccine to UN agencies for childhood immunisation globally, it added. "Our hexavalent vaccine EasySix, which meets the highest standards of safety and efficacy, will have a meaningful impact on the lives of millions of newborns in the developing world," Panacea Biotec Chairman and MD Rajesh Jain said. DFC Deputy CEO Nisha Biswal said the organisation's partnersh

A combined 2.1 million equity shares of the company had changed hands till 02:50 PM, and there are pending buy orders for nearly 100,000 shares on the NSE and BSE.

Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Panacea Biotech announced the launch of production of the Russian Sputnik V vaccine against coronavirus

Serum Institute of India CEO Adar Poonawalla offloaded his entire stake in Panacea Biotec amounting to 5.15 per cent shareholding of the firm for Rs 118 crore, through an open market transaction

Serum Institute of India Private Limited, the world's largest vaccine manufacturer by number of doses produced and sold globally, held 4.98 per cent stake in Panacea Biotech

The Russian Direct Investment Fund and Panacea Biotec announced cooperation to produce 100 million doses per year of Sputnik V

Ircon International board approved the issue of bonus shares in the ratio of 1:1

On December 3, 2020, Serum Institute of India Private Limited sold 309,559 equity shares, representing 0.50 per cent equity of Panacea Biotec, at Rs 243.32 per share

The firm is set to make 500 million doses of the vaccine, which will then be supplied to the JV (based in the Republic of Ireland).

Medical devices industry has potential to attract Rs 70,000 crore in 5 years

The stock up 13% to Rs 255 after the company gets certificate of GMP compliance with manufacturing authorization for 22 medicinal products from state service of Ukraine on medicines & drugs control.

The stock hit a 52-week high of Rs 254, up 15% on BSE in early morning trade